Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ovid Therapeutics Inc. (Nasdaq: OVID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ovid is a New York‑based biopharmaceutical company developing small molecule medicines for brain conditions driven by neuronal hyperexcitability, and its filings offer detailed insight into this strategy, its capital structure and governance.
Investors can review current reports on Form 8‑K, where Ovid reports material events such as positive Phase 1 data for OV329 and OV350, leadership succession plans, private placement financing agreements involving Series B convertible preferred stock and warrants, and transactions like the sale of future ganaxolone royalty rights to Immedica Pharma AB. Other 8‑K items describe Nasdaq listing compliance developments, including bid price notifications, transfers to the Nasdaq Capital Market and subsequent confirmations of regained compliance.
Definitive proxy statements on Schedule 14A, such as the company’s special meeting materials, outline proposals to increase authorized common shares, approve conversions of preferred stock and warrant exercises related to PIPE financings, and authorize reverse stock split ranges. These documents also describe how Ovid seeks stockholder approval for securities issuances under Nasdaq listing rules.
Through Stock Titan, users can monitor Ovid’s real‑time filing activity from EDGAR, including 10‑K and 10‑Q reports when available, as well as Forms 3, 4 and 5 that disclose insider holdings and transactions. AI‑powered tools help summarize lengthy filings, highlight key sections on clinical pipeline strategy, financing terms, listing status and executive arrangements, and make it easier to interpret complex legal and financial language.
For anyone analyzing OVID stock, this filings page serves as a centralized view of Ovid Therapeutics’ official regulatory record, spanning clinical updates, capital markets transactions, governance decisions and listing‑related communications.
Ovid Therapeutics called a virtual special meeting to seek stockholder approval for key actions tied to its October 2025 PIPE financing. The Board asks investors to approve an increase in authorized common shares to 315,000,000, the issuance of shares upon conversion of Series B Preferred Stock and exercise of related warrants, and the issuance of securities purchased by the CEO under Nasdaq rules.
The PIPE provided initial gross proceeds of approximately $80.8 million, with aggregate gross proceeds of up to $175.1 million if all warrants are exercised. The financing included 57,722 shares of Series B Preferred Stock that automatically convert into 1,000 common shares each after stockholder approval, plus Series A Warrants for up to 38,481,325 shares and Series B Warrants for up to 28,861,000 shares, each with a $1.40 exercise price and beneficial ownership caps up to 19.99%.
The meeting is on December 11, 2025 at 9:00 a.m. ET via www.virtualshareholdermeeting.com/OVID2025SM. Shares outstanding were 71,212,353 as of October 31, 2025. If Proposals 1 and 2 do not pass, the Company must hold additional meetings every 90 days to seek approval.
Ovid Therapeutics (OVID) filed a preliminary proxy for a December 11, 2025 virtual special meeting seeking three approvals tied to its October 2, 2025 PIPE financing. The Board asks stockholders to: (1) amend the charter to increase authorized common stock from 125,000,000 to 315,000,000; (2) approve the issuance of shares upon conversion of 57,722 shares of Series B preferred (automatically converts into 1,000 common per preferred share after approval) and upon exercise of Series A Warrants for up to 38,481,325 shares and Series B Warrants for up to 28,861,000 shares, consistent with Nasdaq Rule 5635(d); and (3) approve the CEO’s participation under Nasdaq Rule 5635(c) (71 Series B, 47,333 Series A Warrants, 35,500 Series B Warrants).
The PIPE generated initial gross proceeds of approximately $80.8 million, with aggregate gross proceeds of up to $175.1 million if all warrants are exercised. Warrants have a $1.40 exercise price; Series A Warrants are exercisable after stockholder approval and terminate on the earlier of a 30‑day window following an OV4071 regulatory milestone (with an effective resale registration) or October 6, 2030; Series B Warrants expire October 6, 2030 and include a price‑triggered mandatory exercise. Both instruments include beneficial ownership caps up to 19.99%.
Ovid Therapeutics (OVID) called a virtual Special Meeting on December 11, 2025 to seek stockholder approval for actions tied to an October 2, 2025 PIPE financing. The Board asks holders to approve: (1) an increase in authorized common stock to 315,000,000 shares; (2) the issuance of shares upon conversion of 57,722 shares of Series B Preferred Stock into 57,722,000 common shares and the exercise of warrants for up to 67,342,325 common shares, consistent with Nasdaq Listing Rule 5635(d); and (3) issuance of securities purchased by the CEO under Nasdaq Listing Rule 5635(c).
The PIPE generated initial gross proceeds of approximately $80.8 million, with up to $175.1 million in aggregate gross proceeds if all warrants are exercised, before fees and expenses. Each warrant has a $1.40 exercise price. If Proposals 1 and 2 are approved, Series B automatically converts two business days after the meeting, and the warrants become exercisable, each subject to stated beneficial ownership limits. The company notes that issuing additional shares may dilute earnings per share and voting power.
Ovid Therapeutics filed an Form 8-K disclosing a material event and attaching key transaction documents. The filing includes a Securities Purchase Agreement dated October 2, 2025 between Ovid and certain investors, a Certificate of Designation for Series B Convertible Preferred Stock, forms of Series A, Series B and Pre-Funded warrants, a Registration Rights Agreement, and a Press Release dated October 3, 2025. The cover page interactive XBRL is embedded, and the filing is signed by Jeffrey Rona, Chief Business and Financial Officer. The document list indicates a financing-related transaction with registration and governance documents filed as exhibits; specific economic terms, amounts, and closing confirmation are not provided in the text supplied.
Ovid Therapeutics Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. Nasdaq formally notified the company that it now meets Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, and that the compliance matter is closed.
This means Ovid’s common stock, listed on the Nasdaq Stock Market under the symbol OVID, is no longer at risk from this specific deficiency notice, helping preserve its current exchange listing status.
Ovid Therapeutics Inc. reported unaudited results for the quarter ended June 30, 2025 showing $38.3 million in combined cash, cash equivalents and marketable securities and total assets of $77.4 million, down from $92.2 million at December 31, 2024. Revenue for the three months was $6.3 million versus $0.2 million a year earlier, driven primarily by a $6.3 million payment recognized in connection with the amendment to the Marinus/Immedica arrangement (with $0.7 million recorded as deferred revenue). Operating expenses declined to $11.3 million from $20.7 million, with research and development spending down to $6.5 million and general and administrative to $4.9 million.
The company recorded a net loss of $4.7 million for the quarter and $14.9 million for the six months, and has an accumulated deficit of $319.2 million and working capital of $33.2 million. Management states existing cash and securities are not sufficient to fund current operating plans through the next 12 months and is evaluating strategic alternatives. Takeda discontinued the soticlestat program and prior royalty monetization was reduced to zero; Nasdaq notified the company of a minimum bid deficiency, the company obtained approval to transfer to the Nasdaq Capital Market and authorized a potential reverse stock split option.
Ovid Therapeutics reported that it furnished a press release with business updates and its second quarter 2025 financial results as Exhibit 99.1. The Company disclosed it had not regained compliance with Nasdaq's minimum $1.00 closing bid requirement after the initial cure period and therefore will transfer its common stock to the Nasdaq Capital Market where it will continue trading under the symbol OVID.
The Nasdaq approved the transfer and granted the Company an additional 180-calendar-day compliance period through February 9, 2026 to regain the minimum bid price. The Company said it will monitor the closing bid price and may pursue options to regain compliance, including a reverse stock split, and noted that failure to regain compliance could lead to delisting with the right to appeal.